Physician profile
Selyne E Samuel
NPI 1447538590
$3,658.18
in general payments reported to CMS, 2019-2025
14 companies · $68.88 in 2025
The $68.88 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.38 · 2020: $42.53 · 2023: $1,567 · 2024: $1,896 · 2025: $68.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,360 · Travel and Lodging: $1,258 · Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,360.00 |
| Travel and Lodging | $1,258.31 |
| Food and Beverage | $913.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,789.23 | 2024 | Axoguard Nerve Protector, Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector |
| Merit Medical Systems INC | $1,479.48 | 2023 | Savi Scout |
| Merck Sharp & Dohme LLC | $170.59 | 2023-2025 | Keytruda, Lynparza |
| Focal Therapeutics, INC. | $30.75 | 2020 | |
| Acell, INC. | $26.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.71 | 2024 | |
| Baxter Healthcare | $24.19 | 2019 | |
| Coopersurgical, INC. | $21.89 | 2025 | Onetrac Lx |
| Astrazeneca Pharmaceuticals LP | $17.69 | 2023 | Enhertu |
| Bioptics, INC. | $17.36 | 2019 | |
| Medtronic, INC. | $15.04 | 2023 | V-Loc 180 |
| Biom'Up Sa | $14.90 | 2019 | |
| Solventum Corporation | $13.64 | 2024 | V.A.C.Ulta, V.A.C. Veraflo, Activ.A.C. |
| Medtronic USA, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selyne Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.